Status:
COMPLETED
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
CML
Imatinib
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study is locally amended study from CSTI571K2301 to evaluate the efficacy and safety of high-dose Glivec in Korean patients group with chronic phase of CML. Molecular response at 60 months after ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- TOPS(CSTI571K2301) participant patients who are taking Glivec more than 400 mg daily as 30 July, 2010, the close date of TOPS
- Patients who provided written informed consent prior to participation to this study
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01216085
Start Date
August 1 2010
End Date
July 1 2011
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational Site
Seoul, South Korea, 01008